Xpovio Combo Significantly Extends Survival in RRMM, Trial Results Show
Adding Xpovio (selinexor) to Velcade (bortezomib) and low-dose dexamethasone significantly extends survival without signs of disease worsening in people with…
Patricia Inácio, PhD, science writer — 
Articles by Patricia Inácio
Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says
Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive…
Kleo’s KP1237 Therapy Soon Will Enter Clinical Testing, Following FDA’s Grant of New Drug Status
KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for…
FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily…
Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are…
CHMP Recommends EU Approval of Darzalex Combo as First-line Treatment for Transplant-eligible Myeloma Patients
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Darzalex (daratumumab), in combination with standard pre-transplant therapy, for the treatment of…
Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show
Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who…
Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show
Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly…
Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan…
Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports
Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst…
